
Studies Highlight Unmet Needs and Cost-Effectiveness of SSO2 Therapy for Severe Heart Attack Patients
ZOLL®, an Asahi Kasei company specializing in medical devices and software solutions, has announced the results of two significant studies on the economic burden of heart failure resulting from severe heart attacks and the long-term cost-effectiveness of SuperSaturated Oxygen (SSO2)…












